Houston, Texas, Jun 17, 2020 (Newsfile Corp via COMTEX) -- Houston, Texas--(Newsfile Corp. - June 17, 2020) - Much like we saw with cannabis, U.S. attitudes are positive shifting for psychedelics.
In fact, according to new research from research firm, Green Horizons, up to 38% of adults in the U.S. believe psilocybin mushrooms should be legal, as reported by High Times . Up to 25% say psilocybin should be legal under limited circumstances.
"When it comes to psychedelics, there are many parallels with the movement to legalize cannabis. In both cases, education is paramount," said Adriana Waterston, Green Horizon's SVP of Insights and Strategy, in a press release. "Psychedelics, like cannabis, have been tied to a negative, highly stigmatized image for many years. Science, however, is showing us that psychedelics demonstrate tremendous promise for certain chronic psychological illnesses, even those that have been treatment-resistant. As we continue to study psychedelics and evidence for their benefits mounts, we can expect support for legalization to follow."
In addition, psilocybin is quickly becoming one of the most popular topics in the medical research community, in the press, and even among investors.
Even states across the U.S. have even begun to decriminalize the use of psilocybin, including Denver, Oakland, and Santa Cruz just decriminalized the possession of products containing psilocybin or psilocin. Washington, D.C. could vote by November 2020 to legalize it as well.
All as clinical trials from major institutions find that psychedelic treatments, like psilocybin mushrooms can effectively treat obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression, anxiety, and possibly even weight loss. In fact, it could very well help treat the 30 million Americans that currently have an eating disorder.
Psilocybin a Possible Treatment for Weight Loss
Yield Growth Corp.'s /zigman2/quotes/202014329/delayed CA:BOSS 0.00% (otcqb:BOSQF) majority owned subsidiary NeonMind filed a U.S. provisional patent application in the U.S. for the invention relating to therapeutic administration of psilocybin or psilocin, combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues.
The provisional patent is for a proposed guided psychedelic psilocybin therapy protocol using psychotherapy prior to, during and after the psychoactive effects of the Psilocybin are felt by the patient. The psychedelic assisted psychotherapy is designed to assist in gaining insights from positive psychedelic experiences, to be integrated into everyday life and to help plan, prepare and make sense of psychedelic experiences for a therapeutic result.
In addition, NeonMind has retained contract research organization Translational Life Sciences Inc. to design and plan an initial preclinical study using psilocybin which is anticipated to begin in the fall of 2020. The preclinical study is anticipated to provide data to design phase 2 human clinical trials to test Psilocybin as a weight loss treatment. The phase 2 clinical trials are anticipated to begin in 2021, subject to receiving all required regulatory approvals.
For more information, visit the company's website at https://yieldgrowth.com .
MarijuanaStox.com is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news. MarijuanaStox.com is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com , is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/58041
Is there a problem with this press release? Contact the source provider Comtex at firstname.lastname@example.org. You can also contact MarketWatch Customer Service via our Customer Center.
copyright (c) newsfile corp. 2020. all rights reserved